Pharmaceutical

Keymed’s Stapokibart approved by NMPA for seasonal allergic rhinitis

China's NMPA has granted approval for Keymed Biosciences’ supplemental NDA of Stapokibart to treat seasonal allergic rhinitis.

Feb 11, 2025 - 06:00
Keymed’s Stapokibart approved by NMPA for seasonal allergic rhinitis
China's NMPA has granted approval for Keymed Biosciences’ supplemental NDA of Stapokibart to treat seasonal allergic rhinitis.
Read the original article

Tags:

Previous Article

Public health strategies skip patients with rare diseases, says UK study

Next Article

Fourth person receives eGenesis’ gene-edited pig kidney transplant

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

Biogen completes $1.15bn HI-Bio acquisition to expand i...

Jul 4, 2024

Bionomics to advance non-SSRI PTSD candidate to Phase III

Bionomics to advance non-SSRI PTSD candidate to Phase III

Mar 22, 2024

STAT+: House panel passes key PBM reform for sliver of commercial market

STAT+: House panel passes key PBM reform for sliver of ...

Feb 7, 2024